Shenzhen Salubris Pharmaceuticals Co Ltd (Salubris) focuses on the research, development, manufacture and distribution of pharmaceutical products. The company produces and markets medicines to treat diabetes, partial onset seizures, cardiovascular and cerebrovascular indications. It also offers anti-tumor and anti-infective drugs targeting septicemia, meningitis, respiratory, skin and soft tissue, genital and reproductive system infections. Salubris is investigating small molecules and biological therapeutics for the treatment of metabolic, oncology and also bone diseases. The company also develops interventional medical devices for cardiology, cerebrovascular, structural heart and peripheral vascular disease areas. It operates in the US, Germany, France and Japan. Salubris is headquartered in Shenzhen, Guangdong, China.
Headquarters
China
Address
F37, Main Building,Chegong Temple, Lvgem Neo Square,No.6009 Shennan Boulvrd, Futian District, Shenzhen, Guangdong, 518040
Website
www.salubris.cn
Telephone
86 755 83867888
No of Employees
3,454
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
002294 (SHE)
Revenue (2021)
$517.5M
13.9%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
19.3%
(2021 vs 2020)
Market Cap*
$4.4B
Net Profit Margin (2021)
XYZ
4.8%
(2021 vs 2020)
* As of and is in US$
Shenzhen Salubris Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Salubri |
| Small Molecules and Biologic Therapeutics: | |
| Cardiovascular Diseases | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In July, the company secured an approval from the US FDA to conduct clinical trials for the drug SAL0119 in the US. |
| 2022 | Contracts/Agreements | In November, the company entered into a development agreement with Anlong Biopharmaceutical for cooperation in the research and development of RNAi drugs in the field of hypertension. |
| 2022 | Contracts/Agreements | In October, the company entered into an agreement with Shenzhen Alpha Molecular Technology to jointly develop new drugs. |
Competitor Comparison
| Key Parameters | Shenzhen Salubris Pharmaceuticals Co Ltd | Shanghai Pharmaceuticals Holding Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Huadong Medicine Co Ltd | Jiangsu Hengrui Medicine Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shenzhen | Shanghai | Shanghai | Hangzhou | Lianyungang |
| State/Province | Guangdong | Shanghai | Shanghai | Zhejiang | Jiangsu |
| No. of Employees | 3,454 | 47,877 | 38,399 | 14,061 | 20,636 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ye Chenghai | Chairman | Executive Board | - | - |
| Ye Yuxiang | Vice Chairman | Executive Board | 2022 | 49 |
| Yan Jie | Managing Director | Executive Board | 2018 | 51 |
| Yang Jianfeng | Director; Secretary | Executive Board | 2010 | 48 |
| Zhao Songping | Deputy General Manager | Senior Management | 2016 | 53 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward